This trial is evaluating whether GS-2872 will improve 1 primary outcome and 27 secondary outcomes in patients with HIV Infections. Measurement will happen over the course of First dose date up to Week 26.
This trial requires 21 total participants across 4 different treatment groups
This trial involves 4 different treatments. GS-2872 is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
In the developed world, although one in two men is estimated to be cured of HIV, the possibility does not necessarily remain that the HIV infection can be cured. It is important to emphasize the difficulty of achieving and maintaining AIDS-free status, while attempting to maximize the chances for a cure. Failure to maintain effective antiretroviral treatment increases the risk for disease progression, including neurological disease, and may lead to late, often irreversible, neurologic dysfunction. A cure does not necessarily imply remission of HIV infection.
There are a range of symptoms from HIV infection that can either be specific to an infection with HIV or may be caused by secondary infections, which include opportunistic infections. While a high index of suspicion may be required, a combination of symptoms may be present. Those who have symptoms associated with HIV infection should be referred for laboratory testing.
The first-line of treatment for HIV-related complications (i.e., antiretroviral therapy) involves medications and behavioural changes, while referral to specialist clinics for a clinical diagnosis of HIV/AIDS should be considered after some time. The use of the newer HAART/combined antiretroviral therapy in the treatment of HIV in Japan is expanding and many institutions are expanding the number of beds to facilitate treatment in the first instance.\n\nThe development of clinical practice guidelines for the treatment of asthma, diabetes and hypertension is essential for improving the treatment protocols.\n\nAlthough many patients who have recurrent chest infection are treated at any step by antibiotics, many of these patients do not require it.
HIV infections are not caused by a specific disease, but by exposure to blood and semen collected in the course of sexual activity. The disease arises when exposure produces an immune response.\n
The HIV can affect the development of certain cancers. HIV is transmitted by close heterosexual contact and use of intravenous drug use. Risk of developing the cancers may be higher in people infected by the virus.
An estimated 3.5 million new hiv infections are diagnosed in the U.S. each year. theme:
access and cost question: Is treatment with low-dose abiraterone acetate for a long duration of remission in metastatic castration-resistant prostate cancer safe and effective? answer: Low-dose abiraterone acetate provides long-term (62.9 mo) and complete (93%) PSA control in more than 70% of patients with metastatic castration-resistant prostate cancer. Although there are safety concerns, this study suggests that low-dose abiraterone acetate represents the first-line treatment option for patients with metastatic castration-resistant prostate cancer.
Findings from a recent study are highly encouraging. In the future, we must make sure that our research is not only used for evaluating the effectiveness of drugs but also in treatment to improve the quality of life of infected patients.
The clinical use of GS-2872 to alter PSA kinetics in HIV+ subjects is relatively limited because of the high levels of viral contamination in a number of clinical studies to date. This may be due to the need for more sensitive assays to monitor therapeutically relevant concentrations of PSA kinetics in these clinical studies, which are often performed at the highest dose (2.5x) of GS-2872 to test for maximal PSA changes.
Individuals with HIV infection may not be well-served by the current model of care, and participation in clinical trials has the potential to improve care, improve outcomes, and address the gaps in providers' knowledge and practices about HIV and HIV treatment.
On average men acquire HIV before age 25 but women do not; these data are helpful in developing strategies to reduce the number of new HIV infections and their associated burden of disease.
This is the earliest clinical trial investigating the efficacy and safety of the investigational drug, GS-2872. Results are published on F1000 but not available on ClinicalTrials.gov. If available, a "trial results" page is available at F1000.
Serious viral infections, even those without symptoms, are likely to have serious consequences. They should be treated as severely as other viral infections, and precautions taken.